ArticleJournal of veterinary internal medicine
Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Phase 1 Dose Escalation of Single-Agent Mechlorethamine in Dogs With Lymphoma.Veterinary and comparative oncology · 2026Article
- Band Neutrophils Are Observed in Dogs Undergoing Multiagent Chemotherapy Including Vincristine.Animals : an open access journal from MDPI · 2026Article
- Impacts of Vincristine and Prednisolone Chemotherapy on the Canine Gut Microbiota in Dogs Undergoing Treatment for Lymphoma.Veterinary and comparative oncology · 2025Article
- Canine Multicentric Lymphoma: Diagnostic, Treatment, and Prognostic Insights.Animals : an open access journal from MDPI · 2025Review
- Evaluation of Serum YKL-40 in Canine Multicentric Lymphoma: Clinical and Diagnostic Implications.Animals : an open access journal from MDPI · 2024Article
- Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma.Journal of veterinary internal medicineArticle
- Comparison of CHOP-19 and CHOP-25 for treatment of peripheral nodal B-cell lymphoma in dogs: A European multicenter retrospective cohort study.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThis study was performed to determine the ability to escalate drug doses in a 15-week CHOP protocol in dogs with multicentric lymphoma. HYPOTHESIS: We hypothesized that at least 50% of dogs could successfully be escalated in at least 1 drug. Secondary aims were to establish objective response rate (ORR), progression-free interval (PFI), and overall survival time (OST). ANIMALS: Thirty dogs with newly diagnosed multicentric lymphoma were prospectively treated with a 15-week CHOP protocol.
methodsThis was a prospective cohort study. Drug doses that did not cause dose-limiting adverse effects (AEs) were increased using a standardized escalation protocol. AEs and response were assessed using VCOG criteria. Serial blood samples were collected after the first dose of each drug for pharmacokinetic analysis.
resultsOf the 23 dogs with the opportunity to dose escalate, at least 1 drug was successfully escalated in 18 (78%). Vincristine was successfully escalated to 0.8 mg/m
conclusionsDrugs in the CHOP protocol can often be escalated safely with manageable AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.